Oclaro, Inc. (OCLR): Soros Fund Management’s Latest Acquisition and Other New Positions

Page 2 of 2

Last quarter, Mr. Soros’ fund initiated a stake in Endo International plc (NASDAQ:ENDP) by acquiring 1.75 million shares. This stock has already gained 17% year-to-date and is backed by numerous institutional investors. Larry Robbins’ Glenview Capital for example holds 6.85 million shares, while Jacob Gottlieb’s Visium Asset Management owns 5.70 million shares. Furthermore, recent expansion efforts, such as the acquisition of Auxilium Pharmaceuticals, along with third quarter financial results that beat estimates, have inspired a bullish feeling amongst Endo International plc (NASDAQ:ENDP)’s shareholders.

Endo Health Solutions

Soros Fund Management also entered a new position in LendingClub Corp (NYSE:LC) with the purchase of 4.50 million shares. In 2014, the stock gained almost 8%, and while share prices are down more than 4% year-to-date, the equity’s value has grown by 26% over the past month. Investors’ excitement was fueled by the company’s newest partnerships with Google Inc (NASDAQ:GOOG) and Alibaba Group Holding Ltd (NYSE:BABA). The deal with the Chinese eCommerce giant will see LendingClub Corp (NYSE:LC) provide financing for American small businesses that buy from Chinese suppliers.

Finally, Soros Fund Management also disclosed a new holding in Allergan, Inc. (NYSE:AGN) last quarter, which amounted to 494,800 shares. The stock has gained almost 9% year-to-date, after growing by more than 91% in 2014, and is one of Bill Ackman’s top bets. His fund Pershing Square owns 26.64 million shares, accounting for 35% of its equity portfolio, and making it the company’s largest institutional investor. Furthermore, Allergan, Inc. (NYSE:AGN) is set to be acquired by Actavis plc (NYSE:ACT) in a $66 billion deal that is set to be completed in the second quarter of 2015. When the agreement was announced in November, Mr. Soros was smart to add Allegan to his fund’s equity portfolio, as the combination with Actavis is set to result in the creation of the world’s largest pharmaceutical company.

Disclosure: None

Page 2 of 2